Deborah T. Gold
Professor Emeritus in Psychiatry and Behavioral Sciences
In particular, my current research focuses on compliance and persistence with osteoporosis medications. One current study focuses on the impact of race/ethnicity on medication decision making. We are trying to determine the relative weight of cost, convenience, dosing interval, efficacy, and safety in making medication decisions and taking medication on a regular basis as prescribed by a health care provider. I am also on the Steering Committees of two major observational studies with different osteoporosis medications.
Finally, I have worked with voluntary health organizations to translate our research findings into positive real-world outcomes for people with chronic illness. I serve on the Board of Trustees of the National Osteoporosis Foundation and am Chair of its Education Committee. I have also chaired the International Symposium on Osteoporosis (ISO) for the last 8 years.
Claude D. Pepper Older American Independence Centers awarded by National Institutes of Health (Co-Principal Investigator). 1992 to 1997
Osteoporosis And Disability In A Life Care Community awarded by National Institutes of Health (Principal Investigator). 1993 to 1996
Osteoporosis And Disability In Life-Care Community Women awarded by National Institutes of Health (Principal Investigator). 1992 to 1996
Coping With Chronic Illness In Later Life awarded by National Institutes of Health (Principal Investigator). 1988 to 1989
Gold, Deborah T., et al. “A Patient Survey Study of Zoledronic Acid Utilization and Factors Associated with Persistence.” Arthritis & Rheumatology, vol. 66, WILEY-BLACKWELL, Oct. 2014, pp. S509–S509.
Reynolds, Kristi, et al. “Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates.” Qual Life Res, vol. 23, no. 7, Sept. 2014, pp. 2109–20. Pubmed, doi:10.1007/s11136-014-0662-3. Full Text
Nixon, A., et al. “Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function.” Osteoporos Int, vol. 25, no. 6, June 2014, pp. 1775–84. Pubmed, doi:10.1007/s00198-014-2695-4. Full Text
Naegeli, A. N., et al. “Development of the Osteoporosis Assessment Questionnaire--physical Function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function.” Osteoporos Int, vol. 25, no. 2, Feb. 2014, pp. 579–88. Pubmed, doi:10.1007/s00198-013-2448-9. Full Text
George, L. K., and D. T. Gold. Life course perspectives on intergenerational and generational connections. Vol. 16, Jan. 2014, pp. 67–88. Scopus, doi:10.4324/9781315059303. Full Text
Naegeli, A. N., et al. “Development of the osteoporosis assessment questionnaire - Physical function (OPAQ-PF): An osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function.” Osteoporosis International, vol. 25, no. 2, Jan. 2014, pp. 579–88. Scopus, doi:10.1007/s00198-013-2448-9. Full Text
Burge, Russel, et al. “Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study.” Health Qual Life Outcomes, vol. 11, Nov. 2013, p. 189. Pubmed, doi:10.1186/1477-7525-11-189. Full Text
Reynolds, K., et al. “Primary non-adherence to bisphosphonates in an integrated healthcare setting.” Osteoporos Int, vol. 24, no. 9, Sept. 2013, pp. 2509–17. Pubmed, doi:10.1007/s00198-013-2326-5. Full Text
Silverman, S., et al. “Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.” Osteoporos Int, vol. 24, no. 7, July 2013, pp. 2067–77. Pubmed, doi:10.1007/s00198-012-2241-1. Full Text
Gold, D. T. Condition Critical: Compliance and Persistence with Osteoporosis Medications. Jan. 2013, pp. 1909–21. Scopus, doi:10.1016/B978-0-12-415853-5.00082-0. Full Text